|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAB8B |
Gene summary for RAB8B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAB8B | Gene ID | 51762 |
| Gene name | RAB8B, member RAS oncogene family | |
| Gene Alias | RAB8B | |
| Cytomap | 15q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q92930 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51762 | RAB8B | C21 | Human | Oral cavity | OSCC | 6.06e-09 | 4.18e-01 | 0.2678 |
| 51762 | RAB8B | C30 | Human | Oral cavity | OSCC | 2.98e-15 | 7.64e-01 | 0.3055 |
| 51762 | RAB8B | C43 | Human | Oral cavity | OSCC | 3.78e-02 | 3.04e-02 | 0.1704 |
| 51762 | RAB8B | C08 | Human | Oral cavity | OSCC | 1.51e-09 | 1.49e-01 | 0.1919 |
| 51762 | RAB8B | EOLP-1 | Human | Oral cavity | EOLP | 2.51e-21 | 5.90e-01 | -0.0202 |
| 51762 | RAB8B | EOLP-2 | Human | Oral cavity | EOLP | 8.71e-12 | 4.08e-01 | -0.0203 |
| 51762 | RAB8B | NEOLP-1 | Human | Oral cavity | NEOLP | 2.22e-10 | 5.13e-01 | -0.0194 |
| 51762 | RAB8B | NEOLP-2 | Human | Oral cavity | NEOLP | 2.66e-06 | 3.20e-01 | -0.0196 |
| 51762 | RAB8B | male-WTA | Human | Thyroid | PTC | 1.05e-03 | -3.51e-05 | 0.1037 |
| 51762 | RAB8B | PTC03 | Human | Thyroid | PTC | 3.50e-04 | 6.44e-02 | 0.1784 |
| 51762 | RAB8B | PTC04 | Human | Thyroid | PTC | 1.23e-06 | 2.49e-02 | 0.1927 |
| 51762 | RAB8B | PTC05 | Human | Thyroid | PTC | 1.58e-04 | 2.06e-01 | 0.2065 |
| 51762 | RAB8B | PTC06 | Human | Thyroid | PTC | 5.61e-13 | 2.02e-01 | 0.2057 |
| 51762 | RAB8B | PTC07 | Human | Thyroid | PTC | 2.75e-07 | 1.02e-01 | 0.2044 |
| 51762 | RAB8B | ATC09 | Human | Thyroid | ATC | 4.02e-04 | 1.46e-01 | 0.2871 |
| 51762 | RAB8B | ATC11 | Human | Thyroid | ATC | 5.65e-03 | 2.46e-01 | 0.3386 |
| 51762 | RAB8B | ATC12 | Human | Thyroid | ATC | 5.80e-03 | 1.11e-01 | 0.34 |
| 51762 | RAB8B | ATC13 | Human | Thyroid | ATC | 1.25e-27 | 6.38e-01 | 0.34 |
| 51762 | RAB8B | ATC1 | Human | Thyroid | ATC | 1.04e-05 | 2.04e-01 | 0.2878 |
| 51762 | RAB8B | ATC2 | Human | Thyroid | ATC | 8.18e-06 | 1.01e+00 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007259418 | Oral cavity | OSCC | establishment of protein localization to organelle | 284/7305 | 422/18723 | 1.50e-32 | 1.35e-29 | 284 |
| GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
| GO:000660520 | Oral cavity | OSCC | protein targeting | 204/7305 | 314/18723 | 6.78e-21 | 1.13e-18 | 204 |
| GO:00160508 | Oral cavity | OSCC | vesicle organization | 189/7305 | 300/18723 | 2.40e-17 | 2.14e-15 | 189 |
| GO:001703815 | Oral cavity | OSCC | protein import | 136/7305 | 206/18723 | 3.15e-15 | 2.08e-13 | 136 |
| GO:009015018 | Oral cavity | OSCC | establishment of protein localization to membrane | 163/7305 | 260/18723 | 7.13e-15 | 4.47e-13 | 163 |
| GO:007265918 | Oral cavity | OSCC | protein localization to plasma membrane | 169/7305 | 284/18723 | 1.69e-12 | 7.21e-11 | 169 |
| GO:199077816 | Oral cavity | OSCC | protein localization to cell periphery | 190/7305 | 333/18723 | 1.46e-11 | 5.13e-10 | 190 |
| GO:015011517 | Oral cavity | OSCC | cell-substrate junction organization | 70/7305 | 101/18723 | 6.36e-10 | 1.63e-08 | 70 |
| GO:190165316 | Oral cavity | OSCC | cellular response to peptide | 194/7305 | 359/18723 | 4.31e-09 | 9.57e-08 | 194 |
| GO:003286916 | Oral cavity | OSCC | cellular response to insulin stimulus | 114/7305 | 203/18723 | 5.07e-07 | 7.41e-06 | 114 |
| GO:007137510 | Oral cavity | OSCC | cellular response to peptide hormone stimulus | 153/7305 | 290/18723 | 1.23e-06 | 1.63e-05 | 153 |
| GO:004343419 | Oral cavity | OSCC | response to peptide hormone | 208/7305 | 414/18723 | 1.83e-06 | 2.35e-05 | 208 |
| GO:001988220 | Oral cavity | OSCC | antigen processing and presentation | 65/7305 | 106/18723 | 2.69e-06 | 3.32e-05 | 65 |
| GO:00482843 | Oral cavity | OSCC | organelle fusion | 82/7305 | 141/18723 | 3.08e-06 | 3.72e-05 | 82 |
| GO:003286816 | Oral cavity | OSCC | response to insulin | 138/7305 | 264/18723 | 7.54e-06 | 8.15e-05 | 138 |
| GO:00066123 | Oral cavity | OSCC | protein targeting to membrane | 75/7305 | 131/18723 | 1.72e-05 | 1.69e-04 | 75 |
| GO:003134610 | Oral cavity | OSCC | positive regulation of cell projection organization | 176/7305 | 353/18723 | 1.94e-05 | 1.87e-04 | 176 |
| GO:00224068 | Oral cavity | OSCC | membrane docking | 52/7305 | 86/18723 | 4.50e-05 | 3.84e-04 | 52 |
| GO:00901742 | Oral cavity | OSCC | organelle membrane fusion | 63/7305 | 110/18723 | 7.75e-05 | 6.01e-04 | 63 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0453030 | Oral cavity | OSCC | Tight junction | 102/3704 | 169/8465 | 8.68e-06 | 3.93e-05 | 2.00e-05 | 102 |
| hsa04530114 | Oral cavity | OSCC | Tight junction | 102/3704 | 169/8465 | 8.68e-06 | 3.93e-05 | 2.00e-05 | 102 |
| hsa04530210 | Oral cavity | EOLP | Tight junction | 39/1218 | 169/8465 | 1.52e-03 | 5.34e-03 | 3.15e-03 | 39 |
| hsa0453038 | Oral cavity | EOLP | Tight junction | 39/1218 | 169/8465 | 1.52e-03 | 5.34e-03 | 3.15e-03 | 39 |
| hsa0453045 | Oral cavity | NEOLP | Tight junction | 39/1112 | 169/8465 | 2.50e-04 | 1.62e-03 | 1.02e-03 | 39 |
| hsa0453055 | Oral cavity | NEOLP | Tight junction | 39/1112 | 169/8465 | 2.50e-04 | 1.62e-03 | 1.02e-03 | 39 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAB8B | SNV | Missense_Mutation | c.74N>G | p.Leu25Arg | p.L25R | Q92930 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RAB8B | SNV | Missense_Mutation | c.452N>T | p.Ser151Ile | p.S151I | Q92930 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RAB8B | SNV | Missense_Mutation | novel | c.607N>T | p.Arg203Cys | p.R203C | Q92930 | protein_coding | tolerated(0.07) | possibly_damaging(0.696) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RAB8B | SNV | Missense_Mutation | c.13N>C | p.Tyr5His | p.Y5H | Q92930 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAB8B | SNV | Missense_Mutation | c.315N>A | p.Asn105Lys | p.N105K | Q92930 | protein_coding | deleterious(0.01) | possibly_damaging(0.844) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RAB8B | SNV | Missense_Mutation | c.441N>A | p.Phe147Leu | p.F147L | Q92930 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RAB8B | SNV | Missense_Mutation | novel | c.347G>T | p.Arg116Ile | p.R116I | Q92930 | protein_coding | deleterious(0.02) | possibly_damaging(0.571) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RAB8B | SNV | Missense_Mutation | rs776912093 | c.603C>A | p.Phe201Leu | p.F201L | Q92930 | protein_coding | tolerated(0.21) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RAB8B | SNV | Missense_Mutation | c.441C>A | p.Phe147Leu | p.F147L | Q92930 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAB8B | SNV | Missense_Mutation | novel | c.292N>G | p.Asn98Asp | p.N98D | Q92930 | protein_coding | deleterious(0.01) | possibly_damaging(0.875) | TCGA-G3-AAV6-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |